{
  "id": "5fe31305a43ad3127800003b",
  "type": "factoid",
  "question": "What is the target of adalimumab?",
  "ideal_answer": "adalimumab is an anti-tumour necrosis factor (tf)-\u03b1 antibody.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/16164218",
    "http://www.ncbi.nlm.nih.gov/pubmed/18680684",
    "http://www.ncbi.nlm.nih.gov/pubmed/30701218",
    "http://www.ncbi.nlm.nih.gov/pubmed/25381481",
    "http://www.ncbi.nlm.nih.gov/pubmed/19707417",
    "http://www.ncbi.nlm.nih.gov/pubmed/29752913",
    "http://www.ncbi.nlm.nih.gov/pubmed/23928807",
    "http://www.ncbi.nlm.nih.gov/pubmed/29171393",
    "http://www.ncbi.nlm.nih.gov/pubmed/21744772",
    "http://www.ncbi.nlm.nih.gov/pubmed/24069534",
    "http://www.ncbi.nlm.nih.gov/pubmed/15379777",
    "http://www.ncbi.nlm.nih.gov/pubmed/16255652",
    "http://www.ncbi.nlm.nih.gov/pubmed/22540283",
    "http://www.ncbi.nlm.nih.gov/pubmed/28516879",
    "http://www.ncbi.nlm.nih.gov/pubmed/19128982",
    "http://www.ncbi.nlm.nih.gov/pubmed/24774505"
  ],
  "snippets": [
    {
      "text": "The objective of this study was to assess the relative importance of local versus systemic interactions between adalimumab and tumour necrosis factor (TNF)-\u03b1 in rheumatoid arthritis (RA), identify localization of the site of adalimumab action and assess the efficacy of local (intra-articular) versus systemic adalimumab administration for treatment of RA",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22540283",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The kinetics of adalimumab permeation to the synovial fluid (0.00422 L/h clearance of permeation) versus the rate of TNF\u03b1 turnover in the affected joints (1.84 pmol/h synthesis rate and 0.877 h(-1) degradation rate constant) are apparently the major parameters that determine the time course of TNF\u03b1 concentrations in the synovial fluid and the TNF\u03b1-neutralizing effects of adalimumab in RA patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22540283",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab is the first fully human monoclonal antibody directed against TNF. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24774505",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab (ADA) is able to induce a comprehensive disease control in RA by achieving clinical, functional and radiographic control",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outcomes in rheumatoid arthritis (RA). They are widely used in clinical practice and drug registries give us information to support their use",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab is a fully human monoclonal antibody directed against tumor necrosis factor-alpha, a central cytokine in the immune response in psoriasis that has already been shown to be an effective target for therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15379777",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab is a human anti-TNF\u03b1 monoclonal antibody that has been reported to demonstrate clinical efficacy and safety, resulting in reversal of epidermal hyperplasia and cutaneous inflammation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "major pathway of TNF\u03b1 elimination from the synovial fluid (\u223c77% for subcutaneous administration, and \u223c72% for intravenous and intra-articular administration of adalimumab 40 mg) is interaction with adalimumab, which reaches the joints following local or systemic administration.CONC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22540283",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "eability of TNF\u03b1, which is excessively secreted in the joints, is even higher than that of adalimumab. As ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22540283",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab is the first fully human monoclonal antibody directed against TNF.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24774505",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Most currently available molecules target TNF-alfa with different strategies (i.e., etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol), IL-6 (tocilizumab), CTLA-4 (abatacept), and B cells (rituximab, belimumab) as they are key mediators in the cascade of inflammation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25381481",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ces in knowledge of the pathogenesis of psoriasis have enabled the development of new drugs that target cytokines (e.g., etanercept, adalimumab, and infliximab, which target TNF \u03b1 , and ustekinumab, which targets the p40 subunit of IL23 and IL12). These drugs ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069534",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There are currently two Food and Drug Administration-approved classes of biologic agents that target tumor necrosis factor-alpha (TNF-alpha): anti-TNF monoclonal antibodies (mAbs) (adalimumab and infliximab), and soluble TNF receptors (etanercept). This st",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19128982",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "meric anti-TNFalpha monoclonal antibody, infliximab, full human anti-TNFalpha monoclonal antibody, adalimumab, and TNF receptor II (p75) -IgGFc fusion protein, etanercept, are widely used in the inflammatory disorders including RA. This review arti",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16164218",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "urrently available molecules target TNF-alfa with different strategies (i.e., etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol), IL-6 (tocilizumab), CTLA-4 (abatacept), and B cells (rituximab, belimumab) as they are key mediators in the cascade of inflammation. Further, small molecu",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25381481",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "clonal antibodies against VEGF and TNF-alpha such as bevacizumab, ranibizumab, infliximab and adalimumab have been used to control neovascularization and inflammation in eye with significant positive results whereas others have been used to target CD20, CD52, CD11a, and IL-2. The growin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21744772",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "eview focuses on five biologics which target either T-cells (alefacept) or TNF-alpha (etanercept, adalimumab and infliximab) or interleukin IL-12/IL-23 (ustekinumab)--their efficacy, safety, patient monitoring and recommended dosage. The purpose of",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928807",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab is a human monoclonal antibody against tumor necrosis factor (TNF) alpha approved for moderate-to-severe plaque-type psoriasis and psoriatic arthritis (PsA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19707417",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In clinical practice patients who have not responded to one TNF antagonist may respond to another TNF antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19707417",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The ADAbs can diminish the therapeutic effects of adalimumab by neutralizing the TNF\u03b1 binding site or increasing its clearance from circulation.M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29752913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab is a fully human monoclonal antibody targeted toward tumor necrosis factor alpha (TNF-alpha).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18680684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab (Humira, Abbott Laboratories) is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16255652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16255652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab is a human monoclonal antibody which targets tumor necrosis factor (TNF)-alpha.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30701218",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "TNF, TNF\u03b1, Tumor Necrosis Factor alpha"
}